A detailed history of Scientech Research LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Scientech Research LLC holds 39,262 shares of NTLA stock, worth $580,684. This represents 0.16% of its overall portfolio holdings.

Number of Shares
39,262
Previous 47,101 16.64%
Holding current value
$580,684
Previous $1.05 Billion 23.46%
% of portfolio
0.16%
Previous 0.22%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $154,585 - $214,475
-7,839 Reduced 16.64%
39,262 $807 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $538,217 - $731,782
26,884 Added 132.98%
47,101 $1.05 Billion
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $232,864 - $320,652
9,776 Added 93.63%
20,217 $556 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $241,813 - $337,661
10,441 New
10,441 $318 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.12B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Scientech Research LLC Portfolio

Follow Scientech Research LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scientech Research LLC, based on Form 13F filings with the SEC.

News

Stay updated on Scientech Research LLC with notifications on news.